New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
11:02 EDTALXNAlexion:Data show substantial improvement with Soliris in patients with STEC-HUS
Alexion Pharmaceuticals announced the presentation of 28-week data from all enrolled patients in a multi-center trial of eculizumab, Soliris, in patients who developed Shiga-toxin-producing E. coli hemolytic uremic syndrome, STEC-HUS, during an outbreak in Germany from May 2011 to July 2011. In the study, eculizumab therapy was associated with rapid and sustained clinical improvements in thrombotic microangiopathy, TMA, and systemic organ complications. The study met its primary endpoint of global assessment of efficacy at 8 weeks with 94% of patients achieving a complete or partial response in systemic TMA and vital organ involvement. Key secondary endpoints were also met with high clinical and statistical significance, including global assessment of efficacy at 28 weeks as well as improvement in hematologic, renal and neurologic functions. Preliminary findings from an exploratory post hoc, matched-control analysis of patients with severe STEC-HUS receiving eculizumab versus other patients who received current best supportive care during the German epidemic were also reported, and showed that eculizumab treatment was associated with consistently higher rates of renal and neurological function improvement at weeks 8 and 28.1
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
06:34 EDTALXNAlexion cuts FY!5 non-GAAP EPS to $4.70-$4.80 from $5.60-$5.80, consensus $4.98
Subscribe for More Information
06:32 EDTALXNAlexion reports Q2 Soliris sales $635.98M
Subscribe for More Information
06:32 EDTALXNAlexion reports Q2 non-GAAP EPS $1.44, consensus $1.38
Subscribe for More Information
July 29, 2015
15:08 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information
July 28, 2015
07:20 EDTALXNBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
08:38 EDTALXNAnalysts divided on Biogen following $85 selloff
Subscribe for More Information
06:28 EDTALXNAlexion resumed with an Overweight at JPMorgan
Target $249.
July 22, 2015
09:28 EDTALXNBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
July 21, 2015
07:05 EDTALXNOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use